Gland Pharma Ltd

- There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript. - The company reported a strong cash position with INR28,201 million in cash and cash equivalents and a net cash position of INR25,413 million after accounting for Cenexi's debt. - Capital expenditures are ongoing, primarily funded from existing resources, including investments in Pashamylaram plant expansion and Cenexi. - Management discussed improving operational performance and completing capex cycles within one to two years but did not indicate any external fundraising need. - The focus is on internal cash flow generation and optimizing working capital, with cash flow from operations at INR6,436 million for H1 FY25. Hence, based on the transcript, there are no announced plans for raising funds via new debt or equity.

- Cenexi: Ongoing capex to commercialize technology transfers; full utilization expected by Q1 next year. - Recent investment of EUR7.19 million at Cenexi focused on new capacity and de-bottlenecking. - New high-capacity ampoule line at Fontenay plant to start commercial production in January 2025. - Planned new lines at Cenexi include PFS line, Ampoule line, and others, aiming for asset turn of 1x-2x midterm. - INR1,037 million capex this quarter mainly for modular expansion at Pashamylaram and Cenexi. - Investment in GLP capabilities planned to capture European market demand. - Expansion in biologics manufacturing with strategic collaborations like the one with Dr. Reddy's at Genome Valley. - Annual maintenance shutdowns expected, used to install new capacity, e.g., ~3-4 weeks shutdown in August annually.

- US business expects low double-digit top-line growth driven by new launches in H2 and stabilization of the base business. - Saudi Arabia (ROW) business expected to normalize with sales picking up in Q3 and Q4, contributing to growth. - New product contributions in the US for H1 FY25 were about INR60 crores; launches continue each quarter, supporting growth. - ROW markets showing mixed trends; although some regions like Brazil are steady, Saudi Arabia expects resumed demand. - Base business grew 9% YoY in H1 FY25, with continued steady growth expected, targeting low double-digit growth for the full year. - Cenexi aims for EBITDA-positive by Q4 FY25 with medium-term revenue growth beyond EUR 200 million, following capacity expansions. - Volume growth in the US was about 13% YoY and 5% QoQ, indicating solid demand. - Strategic biologics CDMO collaborations expected to contribute from FY26 onwards.

- Cenexi aims for EBITDA breakeven in Q4 FY25 and expects to reach low single-digit EBITDA next year, progressing to ~10% EBITDA margin by FY27 as new capacities come online. - Base business maintains strong operational performance with stable 34% EBITDA margin and 5% year-over-year EBITDA growth in H1 FY25. - Overall group EBITDA margin currently at 21%, impacted by Cenexi losses; improvement expected as Cenexi’s expanded capacities commercialize over next 1-2 years. - US and ROW markets expected to drive low double-digit revenue growth, supported by new product launches, contract wins (e.g., Enoxaparin), and normalization in ROW markets like Saudi Arabia. - Continued investment in R&D (~4.6-4.7% of revenue) and capex to unlock higher asset turns and future growth (e.g., Pashamylaram expansion, new lines at Cenexi). - Management confident in long-term profitability improvements driven by expanded capabilities and European market presence through Cenexi.

- Cenexi is undertaking new capacity expansions, including a high-capacity ampoule line (starting Jan 2025) and other lines, indicating an active pipeline of orders. - The Normandy site at Cenexi is currently impacting overheads due to low asset turnover but new commercial capacities are expected to enhance order fulfillment. - There is a contract manufacturing agreement with Dr. Reddy’s for biologics, leaving room for additional CDMO partnerships, implying further incoming orders. - Sales delays in Saudi Arabia resulted in delayed tender off-take, which is expected to pick up in Q3/Q4 FY25. - New product launches (6 in the last quarter, 4 in US) continue to contribute to growth, supporting an active order book. - Target for Cenexi to reach positive EBITDA by Q4 FY25 supported by increased revenues above EUR 200 million, reflecting a growing order backlog.